The inactivity of certain genes plays a fundamental role in the prognosis of acute lymphoblastic leukemia (ALL) as well as in response to treatment, according to the results of research involving a team made up of specialists from the University Hospital of Navarra and the Centre for Applied Medical Research (CIMA) at the same University of Navarra, as well as the Reina Sofía Hospital in Córdoba, Andalusia.

In concrete, the work confirmed that the inactivation of 13 microRNAs (a type of gene) by an epigenetic mechanism (capable of modulating the functions of the genetic code), is associated with higher mortality amongst patients with ALL. The results open up new therapeutic options on demonstrating the possibility of using these microRNAs as new targets in the treatment of this cancer illness. The conclusions of the research were recently published in the scientific journal with the greatest international impact in its speciality, the Journal of Clinical Oncology.

Involved in the research work was a team made up of specialists from the University Hospital of Navarra and the Centre for Applied Medical Research (CIMA) of the University of Navarra. Specialists from the Reina Sofía Hospital in Córdoba and the Institute of Human Genetics at the Schleswig-Holstein University Hospital, Kiel Campus in Germany also participated in the study and the publication of results.